Snowden Capital Advisors LLC Exelixis, Inc. Transaction History

Snowden Capital Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $28,783 - $33,458	1,924 Added 7.94%	26,170 $419,000
Q3 2022 Nov 09, 2022	BUY	$15.68 - $22.27 $122,413 - $173,861	7,807 Added 47.49%	24,246 $380,000
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $286,696 - $380,727	16,439 New	16,439 $342,000
Q1 2020 Jan 08, 2024	SELL	$14.46 - $21.8 $1.08 Million - $1.63 Million	-74,900 Closed	0 $0
Q4 2019 Jan 08, 2024	BUY	$15.15 - $18.89 $72,720 - $90,672	4,800 Added 6.85%	74,900 $13.2 Million
Q3 2019 Jan 08, 2024	SELL	$17.68 - $22.65 $25.3 Million - $32.4 Million	-1,429,900 Reduced 95.33%	70,100 $12.4 Million
Q2 2019 Jan 08, 2024	BUY	$18.93 - $24.75 $28.4 Million - $37.1 Million	1,500,000 New	1,500,000 $15 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Snowden Capital Advisors LLC with notifications on news.